Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO plus IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227

被引：1
|
作者：
Peters, S. [1 ]
Penrod, J. [2 ]
Li, J. [2 ]
Lubinga, S. [2 ]
Gupta, R. [2 ]
Bushong, J. [2 ]
Rizzo, J. [2 ]
Ramalingam, S. [3 ]
机构：
[1] Lausanne Univ Hosp, Dept Oncol UNIL CHUV, Lausanne, Switzerland
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Emory, Winship Canc Inst, Atlanta, GA USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10P
引用
收藏
页码：S32 / S33
页数：2
相关论文
共 50 条
  • [31] Nivolumab (Nivo) plus platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227.
    Borghaei, Hossein
    Hellmann, Matthew David
    Paz-Ares, Luis G.
    Ramalingam, Suresh S.
    Reck, Martin
    O'Byrne, Kenneth John
    Bhagavatheeswaran, Prabhu
    Nathan, Faith Ellen
    Brahmer, Julie R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [32] Nivolumab (NIVO) plus chemotherapy (chemo) or NIVO plus ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first report of the CheckMate 648 study
    Greil, R.
    Chau, I
    Doki, Y.
    Ajani, J. A.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H
    Adenis, A.
    el Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, Ignez M.
    Holtved, E.
    Xynos, I
    Liu, X.
    Lei, M.
    Kondo, K.
    Kato, K.
    Kitagawa, Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 81 - 82
  • [33] Five-year outcomes with first-line (1L) nivolumab plus ipilimumab plus chemotherapy (N plus I plus C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA.
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Schenker, Michael
    Bordenave, Stephanie
    Cobo, Manuel
    Juan-Vidal, Oscar
    Reinmuth, Niels
    Richardet, Eduardo
    Felip, Enriqueta
    Menezes, Juliana
    Cheng, Ying
    Mizutani, Hideaki
    Carbone, David Paul
    Lu, Shun
    John, Tom
    Aoyama, Takekazu
    Mahmood, Javed
    Hu, Nan
    Eccles, Laura
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
    Chau, Ian
    Doki, Yuichiro
    Ajani, Jaffer A.
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Freitas Melro Braghiroli, Maria Ignez
    Holtved, Eva
    Xynos, Ioannis
    Liu, Xuan
    Lei, Ming
    Kondo, Kaoru
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (18)
  • [35] CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in hemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC)
    Paz-Ares, L.
    Brahmer, J.
    Hellmann, M. D.
    Reck, M.
    O'Byrne, K.
    Borghaei, H.
    Geese, W. J.
    Lu, H.
    Nathan, F. E.
    Ramalingam, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [36] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722
    Mok, T. S. K.
    Nakagawa, K.
    Park, K.
    Ohe, Y.
    Girard, N.
    Kim, H. R.
    Wu, Y-L.
    Gainor, J.
    Lee, S-H.
    Chiu, C-H.
    Sang-We, K.
    Cheng-Ta, Y.
    Liang, W.
    Wu, L.
    Lin, M-C.
    Samol, J.
    Zhang, X.
    Sylvester, J.
    Li, S.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2022, 33 : S1561 - S1562
  • [37] First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
    Makoto Nishio
    Yuichiro Ohe
    Satoshi Ikeda
    Toshihide Yokoyama
    Hidetoshi Hayashi
    Tatsuro Fukuhara
    Yuki Sato
    Hiroshi Tanaka
    Katsuyuki Hotta
    Shunichi Sugawara
    Haruko Daga
    Isamu Okamoto
    Kazuo Kasahara
    Tateaki Naito
    Li Li
    Ravi G. Gupta
    Judith Bushong
    Hideaki Mizutani
    International Journal of Clinical Oncology, 2023, 28 : 1354 - 1368
  • [38] First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1
    Nishio, Makoto
    Ohe, Yuichiro
    Ikeda, Satoshi
    Yokoyama, Toshihide
    Hayashi, Hidetoshi
    Fukuhara, Tatsuro
    Sato, Yuki
    Tanaka, Hiroshi
    Hotta, Katsuyuki
    Sugawara, Shunichi
    Daga, Haruko
    Okamoto, Isamu
    Kasahara, Kazuo
    Naito, Tateaki
    Li, Li
    Gupta, Ravi G.
    Bushong, Judith
    Mizutani, Hideaki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (10) : 1354 - 1368
  • [39] Event-free survival (EFS) with neoadjuvant nivolumab (NIVO) plus platinum- doublet chemotherapy (chemo) versus chemo by surgical outcomes in resectable non-small cell lung cancer (NSCLC) from CheckMate 816
    Spicer, Jonathan
    Wang, Changli
    Tanaka, Fumihiro
    Chen, Ke-Neng
    Ito, Hiroyuki
    Liberman, Moishe
    Chen, Qixun
    Girard, Nicolas
    Lu, Shun
    Provencio, Mariano
    Mitsudomi, Tetsuya
    Awad, Mark
    Felip, Enriqueta
    Swanson, Scott
    Forde, Patrick
    Cai, Junliang
    Mahmood, Javed
    Hu, Nan
    Tran, Phuong
    Broderick, Stephen
    LUNG CANCER, 2023, 178 : S26 - S27
  • [40] Nivolumab (NIVO) plus ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1
    Reck, M.
    Ciuleanu, T. E.
    Pluzanski, A.
    Lee, J. S.
    Caro, R. Bernabe
    Linardou, H.
    Burgers, J.
    Gallardo, C.
    Nishio, M.
    Peters, S.
    Paz-Ares, L. G.
    Hellmann, M. D.
    Borghaei, H.
    Ramalingam, S. S.
    O'Byrne, K.
    Hu, N.
    Bushong, J.
    Eccles, L.
    Grootendorst, D.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S1430 - S1431
12345